<unk>  is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows<unk> ’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion. The pharmacokinetics of<unk>  has allow it to rapidly achieve steady-state concentrations with a clearance of 50 L/h and a half-life of 2.6 to 3.3 minutes. Cessation of its administration is associated with rapid removal, and normal platelet function is restored within 1 hour.
Cangrelor
Cetrorelix
Riociguat
Vericiguat
Prokarin
Prasugrel
Coronaridine
Aprepitant